Piper Sandler raised the firm’s price target on Karyopharm (KPTI) to $16 from $8 and keeps an Overweight rating on the shares. The firm notes Karyopharm will report Phase III XPORT-EC-042 data on selinexor in TP53 wild-type advanced/recurrent endometrial cancer in mid-2026.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KPTI:
- Karyopharm price target lowered to $16 from $23 at RBC Capital
- Karyopharm price target lowered to $8 from $12 at Piper Sandler
- Karyopharm Strengthens Liquidity With New Equity Financing
- Karyopharm price target lowered to $15 from $21 at Baird
- Karyopharm price target lowered to $8 from $15 at H.C. Wainwright